Direct-to-Consumer Genetic Testing for Cardiovascular Disease
Published: March 13, 2025
- A range of direct-to-consumer genetic tests (DTC-GTs) are increasingly available and more affordable as technology advances, yet the risks, benefits, potential clinical utility, and limitations of these tests are not well defined.
- Part of the challenge in evaluating risks and benefits of DTC-GTs is the variability in the tests available as well as limited US Food and Drug Administration (FDA) oversight.
- This scientific statement summarizes the state of the science in DTC-GT, provides an update on the genetic testing industry, and offers approaches and resources for clinicians to evaluate test quality and navigate patient questions.
Supporting Materials
Recommended Reading
- Gene Therapy in Cardiovascular Disease: Recent Advances and Future Directions in Science
- CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy
- Genetic Testing for Heritable Cardiovascular Diseases in Pediatric Patients
- Considerations for Cardiovascular Genetic and Genomic Research With Marginalized Racial and Ethnic Groups and Indigenous Peoples
- Genetic Testing for Inherited Cardiovascular Diseases
- Establishment of Specialized Clinical Cardiovascular Genetics Programs
- Enhancing Literacy in Cardiovascular Genetics
- Genetics and Genomics for the Prevention and Treatment of Cardiovascular Disease